ClearPoint Neuro, Inc.
NASDAQ•CLPT
執行長: Mr. Joseph Michael Burnett
板塊: Healthcare
行業: Medical - Devices
上市日期: 2012-05-22
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
聯絡資訊
120 S. Sierra Avenue, Suite 100, Solana Beach, CA, 92075, United States
888-287-9109
市值
$275.17M
本益比 (TTM)
-11.4
30
股息率
--
52周最高
$30.10
52周最低
$8.63
52周範圍
排名55Top 80.0%
2.6
F-Score
改良版 Piotroski 分析
基於 10 年期基本面
疲弱 • 2.6 / 9 分
評分區間 (0-9)
8-9: 價值優異
6-7: 基本面強勁
4-5: 整體穩健
0-3: 表現疲弱
資料區間: 2016-2025
財務儀表板
Q3 2025 數據
營業收入
$8.86M+9.10%
近4季度走勢
每股收益
-$0.21+16.67%
近4季度走勢
自由現金流
-$3.32M+174.15%
近4季度走勢
2025 Q3 財報亮點
核心亮點
Total Revenue Increased 9% Q3 2025 total revenue reached $8.9M, a 9% increase; 9M revenue grew 12% to $26.6M.
Gross Margin Expansion Noted Q3 Gross Margin improved to 63% compared to 60% last year, driven by favorable revenue mix.
Secured Major Debt Financing Secured $28.7M net proceeds from 2025 NPA issuance, supplementing $3.3M from 2025 SPA offering.
Service Revenue Strong Growth Q3 Service revenue surged 32% to $3.5M, offsetting slight product revenue decline for the quarter.
關注風險
Net Loss Widened Significantly Q3 Net Loss increased 18% to $(5.9M); 9M Net Loss widened 31% to $(17.8M).
Operating Expenses Increased Nine months G&A expenses rose 27% to $11.1M, driven by higher personnel and professional fees.
Debt Covenants Exposure Obligations under 2025 NPA include covenants; failure to comply risks acceleration of outstanding debt principal.
Biologics Regulatory Uncertainty Growth in biologics business depends on timely FDA approval and evolving regulatory criteria for CGTs.
未來展望
IRRAS Acquisition Expected Closing Merger Agreement signed November 6, 2025, with expected closing in the fourth quarter of 2025.
Additional Funding Contingent Agreement secured to access $20.0M additional funding contingent upon successful closing of IRRAS transaction.
Liquidity Position Adequate Management believes current cash balances of $38.2M are sufficient for operations over next twelve months.
Biologics Partner Base Expanding Partner relationships for biologics/drug delivery grew to over 60 as of September 30, 2025.
同行對比
營業收入 (TTM)
$912.10M
$854.40M
$824.50M
毛利率 (最新季度)
83.5%
79.0%
78.8%
關鍵指標
股票代碼 | 市值 | 本益比 (TTM) | 股東權益報酬率 (TTM) | 負債率 |
|---|---|---|---|---|
| TYRA | $1.84B | -17.2 | -41.2% | 2.1% |
| OLMA | $1.77B | -12.9 | -41.5% | 1.3% |
| AXGN | $1.51B | -87.1 | -13.4% | 8.7% |
長期趨勢
近4季度
營業收入
淨利
營運現金流
4季度營業收入複合增長率
4.5%
溫和增長
4季度淨利複合增長率
N/M
盈利狀態轉變
現金流穩定性
0%
現金流需要關注
深度研究
下次財報:2026年3月11日
每股收益:-$0.22
|營業收入:$10.05M
財務數據
電話會議
財務報告
新聞
損益表
資產負債表
現金流量表
財務比率
變化率
損益表 | 過去12個月 |
|---|
無資料